Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05482321 · ClinicalTrials.gov registry record
Pancreas Ultrasound Imaging in type1 Diabetes
A clinical trial of Type1diabetes and Pancreas Inflamed, sponsored by University of Colorado, Denver.
- Recruiting
- Registry status
- 50
- Enrollment target
- 1
- Study location
NCT05482321 is a study of Type1diabetes and Pancreas Inflamed that is actively recruiting participants, run by University of Colorado, Denver. The registered enrollment target is 50 participants, below the 259-participant average among 19 other Type1diabetes trials with a reported enrollment target (81% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05482321, a study of Type1diabetes and Pancreas Inflamed, is actively recruiting participants, sponsored by University of Colorado, Denver.
- RECRUITING
- Registry status
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
The overall goal of this study is to develop and test a novel method involving ultrasound imaging, in order to detect the development of type 1 diabetes. In this study the investigators will first establish a standard operating procedure for measuring pancreas blood flow speed and volume in the pancreas of human subjects. The investigators will then determine 1) whether these pancreas blood flow factors differ between healthy subjects and those who have recently developed type1 diabetes; and 2) how variable measurements are in healthy subjects and subjects that recently developed type1 diabetes, both between subjects and over time. To address these aims the investigators will perform pancreas ultrasound measurements in each subject using an approved injectable 'bubble' contrast agent that allows measurement of pancreas blood flow. The investigators will compare ultrasound measurement with characteristics of the subject's type 1 diabetes, including genetic factors, glucose levels and other circulating factors, as well as other factors that may influence blood flow in the pancreas independent of type1 diabetes. The successful conclusion of this study will indicate whether measuring pancreas blood flow speed/volume will be helpful in monitoring whether type1 diabetes will emerge and thus will allow a large scale study to answer this question.
Conditions Studied
Interventions
- DRUG Definity Suspension for Injection
Study Locations (1)
Colorado
- University of Colorado Anschutz, Barbara Davis Center - Aurora
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2023-02-27 |
| Est. Completion | 2025-09 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05482321
The ClinicalTrials.gov registry entry for NCT05482321 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 259-participant average among 19 other Type1diabetes trials with a reported enrollment target (81% lower). The listed sponsor is University of Colorado, Denver, which has 1,283 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Type1diabetes appearing as the primary indexed condition, and to 1 intervention - of which Definity Suspension for Injection is the first listed.
NCT05482321 reports 1 study location spanning 1 distinct geographic area - top geographies include Colorado.
Frequently Asked Questions
What is clinical trial NCT05482321 about?
NCT05482321 is a clinical study titled "Pancreas Ultrasound Imaging in type1 Diabetes". The overall goal of this study is to develop and test a novel method involving ultrasound imaging, in order to detect the development of type 1 diabetes. In this study the investigators will first establish a standard operating procedure for measuring pancreas blood flow speed and volume in the panc...
What is the current status of trial NCT05482321?
This trial is currently recruiting. The enrollment target is 50 participants. The study started on 2023-02-27. Estimated completion is 2025-09.
What conditions does trial NCT05482321 study?
This clinical trial studies the following conditions: Type1diabetes, Pancreas Inflamed, Insulitis.
What interventions are being tested in trial NCT05482321?
The interventions under investigation include: Definity Suspension for Injection (DRUG).
Who is sponsoring clinical trial NCT05482321?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05482321 being conducted?
This trial has 1 study location across Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type1diabetes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Genetics Of Autoimmunity In Type I Diabetes
RECRUITING
-
Effect of Fasting on Hypoglycemic Counterregulation in Type 1 Diabetes
RECRUITING · NA
-
Health Behavior Intervention for Adults With Type 1 Diabetes
RECRUITING · NA
-
Effects of Ketosis on Brain Function in Patients With T1DM
RECRUITING · NA
-
Very Low Carbohydrate Diets and Glucagon Response in T1DM
RECRUITING · NA
-
Type 1 Diabetes Management Using a Very Low Carbohydrate Versus Standard Diet
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.